A case of recurrent Neisseria gonorrhoeae infection is being evaluated. Which immunological investigation would best detect a complement pathway defect?

Explanation

## Correct Answer: D. Terminal complement (C5-C9) assay Recurrent Neisseria gonorrhoeae infection is a classic presentation of **terminal complement deficiency** (C5-C9 defects), particularly the **membrane attack complex (MAC)** components. Neisseria species are gram-negative diplococci that are highly susceptible to complement-mediated lysis, especially through the terminal complement pathway. Patients with defects in C5, C6, C7, C8, or C9 cannot form the MAC and therefore cannot lyse these organisms, leading to recurrent or disseminated gonococcal infections. The **terminal complement assay (C5-C9)** directly measures the functional integrity of the MAC by assessing the ability of serum to lyse antibody-sensitized erythrocytes or other target cells. This is the gold-standard investigation for detecting complement pathway defects in the context of recurrent Neisseria infections. While early complement components (C1-C4) are involved in classical pathway activation, it is the terminal components that execute the bactericidal effect against Neisseria. In Indian clinical practice, recurrent gonococcal infections warrant immunological workup; terminal complement assay is the most specific and sensitive test for this presentation. The defect is often inherited as an autosomal recessive trait and is more common in certain populations. ## Why the other options are wrong **A. Nitroblue tetrazolium test** — The NBT test detects **phagocytic oxidative burst defects** (e.g., chronic granulomatous disease), not complement pathway abnormalities. Patients with CGD have defective NADPH oxidase and cannot generate reactive oxygen species, but their complement system is intact. This test is irrelevant to recurrent Neisseria infections caused by complement deficiency. **B. Quantitative immunoglobulin levels** — Immunoglobulin quantitation assesses **humoral immunity and antibody production**, not complement function. While antibodies are necessary for opsonization and complement activation, measuring Ig levels does not directly evaluate the complement cascade itself. Patients with normal Ig levels can still have complement defects, making this test non-specific for complement pathway assessment. **C. C1 esterase inhibitor assay** — C1-INH assay is used to diagnose **hereditary angioedema (HAE)**, a condition involving dysregulation of the early classical pathway, not recurrent infections. C1-INH deficiency causes uncontrolled activation of C1, leading to angioedema, not susceptibility to Neisseria. This test is clinically irrelevant to the immunodeficiency pattern presented. ## High-Yield Facts - **Recurrent Neisseria gonorrhoeae** is pathognomonic for **terminal complement deficiency** (C5-C9), particularly MAC defects. - **Terminal complement assay (C5-C9)** is the gold-standard functional test for detecting MAC integrity and complement-mediated bactericidal activity. - **Neisseria species** are highly susceptible to complement-mediated lysis and cannot survive in serum lacking functional MAC. - **C5-C9 deficiency** is inherited as **autosomal recessive** and increases risk of disseminated gonococcal infection (DGI) and meningococcemia. - **Early complement defects (C1-C4)** present with autoimmune phenomena (SLE-like) and pyogenic infections, not Neisseria-specific recurrence. ## Mnemonics **NEISSERIA = MAC defect** **N**eisseria recurrent infection → **M**embrane **A**ttack **C**omplex (C5-C9) deficiency. When you see recurrent Neisseria, think terminal complement. **MAC = C5-C9 = Lysis** **M**embrane **A**ttack **C**omplex = C5, C6, C7, C8, C9. These form the pore that **lyses gram-negative bacteria**. No MAC → no lysis → recurrent infection. ## NBE Trap NBE pairs complement deficiency with immunoglobulin or phagocytic tests to distract from the specific MAC-Neisseria relationship. Students who confuse complement with antibody production or oxidative burst will select wrong options. ## Clinical Pearl In Indian tertiary care settings, a patient presenting with recurrent gonococcal urethritis or disseminated gonococcal infection (DGI) with arthritis-dermatitis syndrome should raise suspicion for terminal complement deficiency. Serum bactericidal assay or terminal complement functional testing is essential before attributing recurrence to treatment failure or reinfection alone. _Reference: Jawetz Melnick & Adelberg's Medical Microbiology Ch. 23 (Neisseria); Harrison's Principles of Internal Medicine Ch. 310 (Complement Disorders)_